Academic Journal

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

التفاصيل البيبلوغرافية
العنوان: A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis
المؤلفون: Laura Calvo-Barreiro, Herena Eixarch, Manuel Ponce-Alonso, Mireia Castillo, Rafael Lebrón-Galán, Leyre Mestre, Carmen Guaza, Diego Clemente, Rosa del Campo, Xavier Montalban, Carmen Espejo
المصدر: Cells, Vol 9, Iss 4, p 906 (2020)
بيانات النشر: MDPI AG, 2020.
سنة النشر: 2020
المجموعة: LCC:Cytology
مصطلحات موضوعية: gut microbiota, probiotics, immune regulation, experimental autoimmune encephalomyelitis, multiple sclerosis, adaptive immunity, Cytology, QH573-671
الوصف: Previous studies in experimental autoimmune encephalomyelitis (EAE) models have shown that some probiotic bacteria beneficially impact the development of this experimental disease. Here, we tested the therapeutic effect of two commercial multispecies probiotics—Lactibiane iki and Vivomixx—on the clinical outcome of established EAE. Lactibiane iki improves EAE clinical outcome in a dose-dependent manner and decreases central nervous system (CNS) demyelination and inflammation. This clinical improvement is related to the inhibition of pro-inflammatory and the stimulation of immunoregulatory mechanisms in the periphery. Moreover, both probiotics modulate the number and phenotype of dendritic cells (DCs). Specifically, Lactibiane iki promotes an immature, tolerogenic phenotype of DCs that can directly induce immune tolerance in the periphery, while Vivomixx decreases the percentage of DCs expressing co-stimulatory molecules. Finally, gut microbiome analysis reveals an altered microbiome composition related to clinical condition and disease progression. This is the first preclinical assay that demonstrates that a commercial probiotic performs a beneficial and dose-dependent effect in EAE mice and one of the few that demonstrates a therapeutic effect once the experimental disease is established. Because this probiotic is already available for clinical trials, further studies are being planned to explore its therapeutic potential in multiple sclerosis patients.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2073-4409
Relation: https://www.mdpi.com/2073-4409/9/4/906; https://doaj.org/toc/2073-4409
DOI: 10.3390/cells9040906
URL الوصول: https://doaj.org/article/b6deee5c63b3455a9fa039ba93dd3855
رقم الانضمام: edsdoj.b6deee5c63b3455a9fa039ba93dd3855
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20734409
DOI:10.3390/cells9040906